Shweta Singh is contesting from Bokaro against BJP’s incumbent MLA Biranchi Narayan. As the daughter-in-law of former MLA Samresh Singh, Shweta aims to leverage her family legacy while addressing pressing local concerns such as education and employment opportunities. Her campaign strategy includes grassroots outreach to connect with voters directly and emphasise her commitment to community development. Given Bokaro's status as a major constituency with a high voter turnout, Shweta's performance could significantly influence Congress's overall standing in Jharkhand.
Home Loan EMI Rate Unchanged: With EMIs steady after the MPC's first 2026 decision, experts say borrowers should reassess loan terms instead of waiting for fresh rate cuts
DoT's Sanchar Saathi initiative has enabled members of the public to report suspected fraudulent communications through its Chakshu facility, available via a web portal and mobile application
Reserve Bank of India Governor Sanjay Malhotra said India's economy remains on a strong footing despite global challenges, helped by stable inflation and steady growth
Makary's comments came after online telehealth company Hims and Hers Health began offering a much cheaper $49 compounded version of Novo Nordisk's new Wegovy weight-loss pill
At 10:45 AM; the Nifty PSU Bank, Nifty Realty and Nifty Auto index were down in the range of 0.67 per cent and 2 per cent, as compared to 0.60 per cent decline in the benchmark Nifty 50.
Commodity rout: Precious metals - Gold, Silver, Platinum have cracked up to 47.5%; base metals - aluminium, copper, zinc, lead and nickel - plunged up to 18% in global markets from January 29 highs.
A major review finds exercise physiology still sidelines women in research, shaping how fitness, training and recovery advice is built, raising questions about how universal health research really is
ASUS has announced six Zenbook and Vivobook laptops in India, expanding its PC lineup with AI-powered and standard models, led by the flagship Zenbook S16 and new Vivobook variants
Alembic Pharmaceuticals said it will miss the first wave of global generic semaglutide launches but is exploring partnerships for a faster entry into the Indian market